Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pipeline
Biotech
Hansoh heralds China’s move from ‘follower’ to ‘frontrunner’
Hansoh gave a bullish assessment of China’s biopharma role, arguing that it is “fully transitioning from the ‘follower’ to the ‘frontrunner’ phase.”
Nick Paul Taylor
Aug 26, 2026 9:33am
Context ends bispecific trial to extend runway deeper into 2027
Aug 6, 2026 5:55am
Sanofi suspends chronic lung disease phase 2 study
Aug 5, 2026 2:50pm
Lilly drops another gene therapy trial from $1B Prevail buyout
Aug 5, 2026 9:10am
Amgen drops ph. 1 obesity drug, upping pressure on MariTide
Aug 4, 2026 4:01pm
Pfizer axes ex-Metsera obesity asset and GIPR prospect
Aug 4, 2026 8:47am
